

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: TDM1/18 - Therapeutic Drugs

Dead line: 13.04.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability												
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>					
<b>Set of samples 1</b>																			
<b>(81) Digoxin</b>																			
Samples and groups		[nmol/L]			10						0			10	10 100%				
Sample A1		0,945	0,21	23	10						0	CRV	1,018 ,0100	36%	0,651	1,39	10	10 100%	
(4) LIA, ILMA		0,925	0,29	31	7	0												7	
Other					3	0													3
													1x 2, 2x 6						
Sample B1		0,771	0,21	27	10						0	CRV	0,846 ,0085	36%	0,541	1,16	10	10 100%	
(4) LIA, ILMA		0,765	0,24	32	7	0													7
Other					3	0													3
													1x 2, 2x 6						
<b>(82) Theophylline</b>																			
Samples and groups		[µmol/L]			4						0			4	4 100%				
Sample A1		83,0	9,5	11	4						0	CRV	88,1 0,88	24%	66,9	110	4	4 100%	
Other					4	0													4
													2x 2, 1x 4, 1x 6						
Sample B1		75,2	7,8	10	4						0	CRV	80,99 0,81	24%	61,5	101	4	4 100%	
Other					4	0													4
													2x 2, 1x 4, 1x 6						
<b>(84) Phenobarbital</b>																			
Samples and groups		[µmol/L]			5						5	5 100%							
Sample A1		72,2	2,0	2,8	5	CVP	70,3	2,1	20%	56,2	84,4	5	5 100%					0	
Other					5	0						5							
													1x 2, 3x 4, 1x 6						
Sample B1		101	5,0	5,0	5	CVP	97,7	2,0	20%	78,1	118	5	5 100%					0	
Other					5	0						5							
													1x 2, 3x 4, 1x 6						
<b>(85) Phenytoin</b>																			
Samples and groups		[µmol/L]			3						3	3 100%							
Sample A1		89,8	12	13	3	CVP	83,3	1,5	20%	66,6	100	3	3 100%					0	
Other					3	0						3							
													1x 4, 2x 6						
Sample B1		27,2	3,4	13	3	CVP	28	0,69	20%	22,4	33,6	3	3 100%					0	
Other					3	0						3							
													1x 4, 2x 6						
<b>(86) Carbamazepin</b>																			
Samples and groups		[µmol/L]			9						9	8 89%							
Sample A1		40,8	3,9	9,4	9	CVP	39,5	0,82	20%	31,6	47,4	9	8 89%					0	
Other					9	0						9							
													1x 1, 3x 2, 3x 4, 2x 6						
Sample B1		38,5	1,6	4,2	9	CVP	38,6	0,80	20%	30,8	46,4	9	9 100%					0	

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: TDM1/18 - Therapeutic Drugs

Dead line: 13.04.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(86) Carbamazepin</b>	[µmol/L]				9							9	8	89%									0
Samples and groups																							
<b>Sample B1</b>		38,5	1,6	4,2	9		CVP	38,6	0,80	20%	30,8	46,4	9	9	100%								0
Other					9	0							9										
							1x 1, 3x 2, 3x 4, 2x 6																
<b>(88) Valproic acid</b>	[µmol/L]				10								10	9	90%								0
Samples and groups																							
<b>Sample A1</b>		639	54	8,5	10		CVP	622	13	20%	497	747	10	9	90%								0
Other					10	0							10										
							1x 1, 3x 2, 4x 4, 2x 6																
<b>Sample B1</b>		285	36	13	10		CVP	279	7,6	20%	223	335	10	9	90%								0
Other					10	0							10										
							1x 1, 3x 2, 4x 4, 2x 6																
<b>Set of samples 2</b>																							
<b>(89) Amicacin</b>	[µmol/L]				2								2	1	50%								0
Samples and groups																							
<b>Sample A2</b>		30,9	5,6	18	2		CVP	32	1,00	20%	25,6	38,4	2	1	50%								0
Other					2	0							2										
							2x 2																
<b>Sample B2</b>		45,9	9,7	21	2		CVP	48,2	1,4	20%	38,5	57,9	2	1	50%								0
Other					2	0							2										
							2x 2																
<b>(90) Gentamicin</b>	[µmol/L]				5								5	5	100%								0
Samples and groups																							
<b>Sample A2</b>		7,94	0,20	2,5	5		CVP	7,66	0,29	31%	5,28	10,1	5	5	100%								0
Other					5	0							5										
							1x 1, 2x 2, 2x 4																
<b>Sample B2</b>		15,8	1,9	12	5		CVP	15,6	0,97	31%	10,7	20,5	5	5	100%								0
Other					5	0							5										
							1x 1, 2x 2, 2x 4																
<b>(92) Vankomycin</b>	[µmol/L]				8								8	7	88%								0
Samples and groups																							
<b>Sample A2</b>		10,6	1,2	11	8		CVP	11	0,47	28%	7,92	14,1	8	8	100%								0
Other					8	0							8										
							1x 1, 1x 2, 4x 4, 1x 6, 1x 99																
<b>Sample B2</b>		26,9	3,5	13	8		CVP	28,8	1,3	28%	20,7	36,9	8	7	88%								0
Other					8	1							8										
							1x 1, 1x 2, 4x 4, 1x 6, 1x 99																
<b>(93) Methotrexate</b>	[µmol/L]				2								2	2	100%								0
Samples and groups																							
<b>Sample A2</b>		0,773	0,01	2,0	2		CVP	0,799	0,031	30%	0,559	1,04	2	2	100%								0
Other					2	0							2										
							1x 2, 1x 4																
<b>Sample B2</b>		2,89	0,29	10	2		CVP	2,79	0,27	30%	1,95	3,63	2	2	100%								0
Other					2	0							2										
							1x 2, 1x 4																